ALFA Filings
Every announcement, straight from the exchange
Every Shukra Pharmaceuticals other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements
Shukra Medtech submitted a revised CA certificate to NSE for its name and symbol change application. The filing requests final exchange approval for the corporate rename.
Shukra Pharmaceuticals Limited has submitted the certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Shukra Pharmaceuticals Limited has announced the direct listing of its equity shares on the NSE Main Board. Trading will commence under the symbol SHUKRAPHAR effective August 14, 2026.
The company filed its quarterly shareholding pattern under Regulation 31(1)(a). This report provides the current distribution of shares among promoter and public shareholders.
Shukra Pharmaceuticals Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026.
Shukra Pharmaceuticals Ltd filed its Annual Secretarial Compliance Report for FY 2025-26. The auditor confirmed statutory compliance despite the company crossing specific regulatory thresholds.